Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Inhibition of Platelet Activation and Aggregation

  • Chapter
Atherosclerosis: Diet and Drugs

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 170))

Abstract

It has recently been established that platelets are involved at all stages of atherosclerotic disease. A major platelet mediated process is the acute vessel closure at the site of atherosclerotic plaque rupture and there is emerging evidence for platelet adhesion to endothelial cells in the early stage of atherosclerotic disease. This, through engagement of other cells, leads to the development of the atherosclerotic plaque. Beside dietary, cholesterol- and lipid-lowering, and other pharmaceutical approaches antiplatelet therapy plays an important part in the treatment of atherosclerosis and its multifarious clinical manifestations. Antiplatelet therapy and the currently approved substances for oral (acetylsalicylic acid, dipyridamole, cilostazol, ticlopidin and clopidogrel) and parenteral (acetylsalicylic acid, abciximab, eptifibatide and tirofiban) administration are discussed in the following section. Attention is given to each single agent and its mechanism of action. Differences in pharmacodynamic and pharmacokinetic properties are elucidated and outlook on future antiplatelet strategies is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ammar T, Scudder LE, Coller BS (1997) In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 95:614–617

    PubMed  Google Scholar 

  • Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106

    Google Scholar 

  • Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86

    Google Scholar 

  • Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, Capra A, Rossi S, Nosotti L, Costantini C, Pietrofeso R (2000) Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)-Hypertension study. Am J Hypertens≥ 13:611–616

    Article  Google Scholar 

  • Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2:10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316:1337–1343

    PubMed  Google Scholar 

  • Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld JW Jr (1987) Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76:125–134

    PubMed  Google Scholar 

  • Basani RB, French DL, Vilaire G, Brown DL, Chen F, Coller BS, Derrick JM, Gartner TK, Bennet JS, Poncz M (2000) A naturally occuring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3. Blood 95:180–188

    PubMed  Google Scholar 

  • Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA (2002) Randomized COMparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE trial. Circulation 106:1470–1476

    Article  PubMed  Google Scholar 

  • Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725–748

    PubMed  Google Scholar 

  • Bednar B, Cook JJ, Holahan MA, Cunnigham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ (1999) Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 94:587–599

    PubMed  Google Scholar 

  • Bennett CL, Conners JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfiled AJ, Feldman MD, Davidson CJ, Tsai HM (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. New Engl J Med 342:1773–1777

    Article  PubMed  Google Scholar 

  • Berkowitz SD, Harrington RA, Rund MM, Tcheng JE (1997) Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 95:809–813

    PubMed  Google Scholar 

  • Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624–629

    PubMed  Google Scholar 

  • Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ (2002) Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39:9–14

    Article  PubMed  Google Scholar 

  • Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, et al. (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313:1369–1375

    PubMed  Google Scholar 

  • CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

    Google Scholar 

  • Chao W, Olson MS (1993) Platelet-activating factor: receptors and signal transduction. Biochem J 292:617–629

    PubMed  Google Scholar 

  • Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation 103:201–216

    PubMed  Google Scholar 

  • Coller BS (1999) Binding of abciximab to αVβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 82:326–336

    PubMed  Google Scholar 

  • Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R (1989) Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 80:1766–1774

    PubMed  Google Scholar 

  • Cosmi B, Rubboli A, Castelvetri C, Milandri M(2001)Ticlopidine versus oral anticoagulation for coronary stenting (Cochrane Review) [CD002133]. Cochrane Database Syst Rev 2001:4

    Google Scholar 

  • De Schryver ELLM for the ESPRIT study group (2003) Dipyridamole in stroke prevention. Effect of dipyridamole on blood pressure. Stroke 34:2339–2342

    Article  PubMed  Google Scholar 

  • Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ Jr, Lynch RJ, Manno PD, et al. (1994) Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for arg-gly-asp. J Med Chem 37:2537–2551

    PubMed  Google Scholar 

  • Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942–1947

    PubMed  Google Scholar 

  • ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:1292–1300

    Google Scholar 

  • Fitzgerald DJ, Roy L, Catella F, FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983–989

    PubMed  Google Scholar 

  • Gachet C (2001) ADP receptors of platelets and their inhibition. Thromb Haemost 86:222–232

    PubMed  Google Scholar 

  • Gawaz M, Neumann FJ, Ott I, May A, Schomig A (1996) Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 94:279–285

    PubMed  Google Scholar 

  • Gilchrist IC, O'shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleimann NS, Talley D, Aguirre F, Davidson C, Runyon J, Tcheng JE (2001) Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 104:406–411

    PubMed  Google Scholar 

  • Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 35:1755–1762

    Google Scholar 

  • Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349:617–620

    PubMed  Google Scholar 

  • Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207

    Article  PubMed  Google Scholar 

  • Hourani SM, Cusack NJ (1991) Pharmacological receptors on blood platelets. Pharmacol Rev 43:243–298

    PubMed  Google Scholar 

  • IMPACT-II investigators (1997) Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II. Lancet 349:1422–1428

    Google Scholar 

  • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17'187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360

    Google Scholar 

  • Jin J, Daniel JL, Kunapuli SP (1998) Molecular basis for ADP-induced platelet aggregation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273:2030–2034

    Article  PubMed  Google Scholar 

  • Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR (1998) A dual thrombin receptor system for platelet activation. Nature 394:690–694

    Article  PubMed  Google Scholar 

  • Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879–887

    PubMed  Google Scholar 

  • Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight G, Farndale RW, Okuma M, Barnes MJ (1998) Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quarternary structure of collagen whereas CD36, Glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 91:491–499

    PubMed  Google Scholar 

  • Keularts IMLW, van Gorp RMA, Feijge MAH, Vuist WMJ, Heemskerk JWM (2000) α2Aadrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem 275:1763–1772

    Article  PubMed  Google Scholar 

  • Kimura Y, Tani T, Kambe T, Watanabe K (1985) Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144–1149

    PubMed  Google Scholar 

  • Klimt CR, Knatterud OL, Stamler J, Meier P (1986) Persantine-Aspirine Reinfarction Study II. Secondary prevention with Persantine and Aspirin. J Am Coll Cardiol 7:251–269

    PubMed  Google Scholar 

  • Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, Skillman J, Couch NP, Whittemore AD, Mannick JA, et al. (1984) Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 96:462–466

    PubMed  Google Scholar 

  • Lele M, Sajid M, Wajih N, Stouffer GA (2001) Eptifibatide and 7E3, but not tirofiban, inhibit αVβ3 integrin mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 104:582–587

    PubMed  Google Scholar 

  • Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403

    PubMed  Google Scholar 

  • Lin EC, Ratnikov BI, Tsai PM, Carron CP, Myers DM, Barbas CF, Smith JM (1997) Identification of a region in the integrin β3 subunit that confers ligand binding specificity. J Biol Chem 272:23912–23920

    Article  PubMed  Google Scholar 

  • MacKenzie AB, Mahaut-Smith MP, Sage SO (1996) Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 271:2879–2881

    Article  PubMed  Google Scholar 

  • Marzilli M, Sambuceti G, Testa R, Fedele S (2002) Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol 40:2102–2109

    Article  PubMed  Google Scholar 

  • Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE (1998) Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97:1680–1688

    PubMed  Google Scholar 

  • Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ (1995) Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 75:559–562

    Article  PubMed  Google Scholar 

  • Monocada S, Korbut R (1978) Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1:1286–1289

    Article  PubMed  Google Scholar 

  • Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW(1999) Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99:2364–2366

    PubMed  Google Scholar 

  • Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A (1981) Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 21:9–15

    PubMed  Google Scholar 

  • Newsholme EA(1978) The control of the mechanism and the hormonal control of adenosine. Essays Biochem 14:82–123

    Google Scholar 

  • Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287–294

    Article  PubMed  Google Scholar 

  • Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G (2001) Platelet-active drugs. The relationships among dose, effectiveness, and side effect. Chest 119(1 Suppl):S39–S63

    Article  Google Scholar 

  • Paul BZS, Ashby B, Sheth SB (1998) Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 102:1204–1211

    Article  PubMed  Google Scholar 

  • Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa inhibitors. Blood 92:3240–3249

    PubMed  Google Scholar 

  • Peter K, Schwarz M, Conradt C, Nordt T, Moser M, Kubler W, Bode C (1999) Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation 100:1533–1539

    PubMed  Google Scholar 

  • Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, Bode C (1999) Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 84:519–524

    Article  PubMed  Google Scholar 

  • Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kubler W, Bode C (2000) Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 102:1490–1496

    PubMed  Google Scholar 

  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al. (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 296:313–316

    Google Scholar 

  • Phillips DR, Scarborough RM (1997) Clinical pharmacology of eptifibatide. Am J Cardiol 80:11B–20B

    Article  PubMed  Google Scholar 

  • Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM (1997) Effect of Ca 2+ on GPIIb-IIIa interactions with integrilin: enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96:1488–1498

    PubMed  Google Scholar 

  • Phillips DR, Charo IF, Parise LV, Fitzgerald LA (1998) The platelet membrane glycoprotein IIb/IIIa complex. Blood 71:831–843

    Google Scholar 

  • RESTORE investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 96:1445–1453

    Google Scholar 

  • Roderick PJ, Wilkes HC, Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35:219–226

    PubMed  Google Scholar 

  • Sanz G, Pajaron A, Alegria E, Coello I, Cardona M, Fournier JA, Gomez-Recio M, Ruano J, Hidalgo R, Medina A, et al. (1990) Prevention of early aorto-coronary bypass occlusion by low dose aspirin and dipyridamole. Circulation 82:765–773

    PubMed  Google Scholar 

  • Savage B, Almus-Jacobs F, Ruggeri ZM(1998) Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94:657–666

    Article  PubMed  Google Scholar 

  • Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R (1999) Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 25:15–19

    PubMed  Google Scholar 

  • Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891–896

    PubMed  Google Scholar 

  • Scarborough RM, Kleiman N, Phillips DR (1999) Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 100:437–444

    PubMed  Google Scholar 

  • Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089

    Article  PubMed  Google Scholar 

  • Schror K (2002) The pharmacology of cilostazol. Diabetes Obes Metab 4:S14–S19

    Article  PubMed  Google Scholar 

  • Schwarz M, Nordt T, Bode C, Peter K (2002) The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, αMβ2). Thromb Res 107:121–128

    Article  PubMed  Google Scholar 

  • Shattil S (1999) Signaling through platelet integrin αIIbβ3: inside-out, outside-in, and sideways. Thromb Haemost 82:318–325

    PubMed  Google Scholar 

  • Siess W, Stifel M, Binder H, Weber PC (1986) Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets. Biochem J 233:83–91

    PubMed  Google Scholar 

  • Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 271:33157–33160

    Article  PubMed  Google Scholar 

  • Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553–15558

    Article  PubMed  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135

    Google Scholar 

  • Stein PD, Collins JJ, Kantrowitz A (1986) Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Arch intern Med 146:468–469

    Google Scholar 

  • Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ (2001) Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103:2572–2578

    PubMed  Google Scholar 

  • Storey F (2001) The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 12:197–209

    PubMed  Google Scholar 

  • Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S (1992) Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20:900–906

    PubMed  Google Scholar 

  • Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro), chimeric 7E3 Fab demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αVβ3 integrins. Circulation 98:1085–1092

    PubMed  Google Scholar 

  • Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H (1988) Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the concentration of vascular smooth muscle. Pharmacology 36:313–320

    PubMed  Google Scholar 

  • Tcheng JE (2000) Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal thrombocytopenia, and retreatment. Am Heart J 139:S38–S45

    Article  PubMed  Google Scholar 

  • Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody FAB 7E3 in high-risk coronary angioplasty. Circulation 90:1757–1764

    PubMed  Google Scholar 

  • Tcheng JE, Talley JD, O'shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ (2001) Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 88:1097–1102

    Article  PubMed  Google Scholar 

  • The ESPRIT trial investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 356:2037–2044

    Google Scholar 

  • The ESPS-2 Group (1997) European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci 151:S1–S77

    Google Scholar 

  • The GUSTO IV-ACS investigators (2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357:1915–1924

    Google Scholar 

  • The Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233–241

    Google Scholar 

  • The Persantine-Aspirin Reinfarction Study research group (1980) Persantine and Aspirin in coronary heart disease. Circulation 3:449–460

    Google Scholar 

  • The PURSUIT trial investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. NEngl J Med 339:436–443

    Google Scholar 

  • The TARGET investigators (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularisation. N Engl J Med 344:1888–1894

    Google Scholar 

  • Thebault JJ, Blatrix CE, Blanchard JF, Panak EA (1975) Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 18:485–490

    PubMed  Google Scholar 

  • Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al. (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105–1111

    PubMed  Google Scholar 

  • Thibault G, Tardiff P, Lapalme G (2001) Comparative specificity of platelet αIIbβ3 integrin antagonists. J Pharmacol Exp Therapy 296:690–696

    Google Scholar 

  • Thompson PD, Zimet R, Forbes WP, Zhang P (2002) Meta-Analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314–1319

    Article  PubMed  Google Scholar 

  • Turrito VT, Weiss HJ, Zimmerman TS, Sussman II (1985) Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 65:823–831

    PubMed  Google Scholar 

  • Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K (1999) Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 353:900

    Article  Google Scholar 

  • Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K (2001) Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 52:333–336

    Article  PubMed  Google Scholar 

  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    PubMed  Google Scholar 

  • Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH (1995) Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 269:H473–H479

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Innere Medizin III (Kardiologie u. Angiologie), Universitäsklinikum Freiburg, Medizinische Universitäsklinik und Poliklinik, Hugstetter Strasse 55, 79106, Freiburg, Germany

    I. Ahrens, C. Bode & K. Peter

Authors
  1. I. Ahrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Bode
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Clinical Chemistry, University Hospital of Zurich, Rämistrasse 100, 8091, Zürich, Switzerland

    Arnold von Eckardstein

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ahrens, I., Bode, C., Peter, K. (2005). Inhibition of Platelet Activation and Aggregation. In: von Eckardstein, A. (eds) Atherosclerosis: Diet and Drugs. Handbook of Experimental Pharmacology, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27661-0_16

Download citation

Publish with us

Policies and ethics

Search

Navigation